Glenmark Pharma Expands US Portfolio with New Acid Regulation Injection

The pharmaceutical landscape in the United States continues to evolve as Glenmark Pharma’s US arm announced the launch of a new injectable formulation aimed at managing metabolic acidosis. 

The company is set to introduce the 8.4% sodium bicarbonate injection USP, expanding its presence in the injectable segment. This development marks another addition to its US portfolio, reinforcing its focus on expanding treatment options for critical care conditions.

Details of the New Launch

The newly approved injection is designed to help control metabolic acidosis, a medical condition that occurs when the body generates excess acid. This imbalance is often seen in conditions such as severe kidney disorders, cardiac arrest, dehydration, uncontrolled diabetes, or shock. 

The 8.4% Sodium Bicarbonate Injection USP comes in a 50 mEq/50 mL (1 mEq/mL) single-dose vial and is both bioequivalent and therapeutically equivalent to the reference listed drug approved in the US market.

According to the company’s exchange filing, the product will be distributed across the US starting in November 2025. It aims to provide an alternative treatment option to healthcare providers and improve patient access to essential injectable medications.

Market Overview

Based on data from IQVIA for the 12 months ending August 2025, the total market for the 8.4% sodium bicarbonate injection (50 mEq/50 mL) recorded annual sales of around $63.8 million. This suggests a stable market demand for the formulation, as it plays a crucial role in managing acid-base imbalances in emergency and intensive care settings.

The company also clarified that its product will be marketed strictly for its approved therapeutic indications, as listed on its official label. While the overall market figure includes both branded and equivalent products, Glenmark’s version is expected to offer comparable clinical outcomes.

Glenmark Pharmaceuticals Share Price Update

As of November 04, 2025, 11:21 AM, the Glenmark Pharmaceuticals share price stood at ₹1,860, down 2.03%. The company’s market capitalisation was ₹52,477 crore, with a P/E ratio of 39.4. The stock recorded a 52-week high of ₹2,286 and a low of ₹1,275. The book value was ₹314, with a dividend yield of 0.13%, ROCE of 19.4%, and ROE of 15.8%.

Read More:Glenmark Secures Global Rights for Next Gen HER2 Targeted Therapy

Conclusion

Through this launch, the company continues to build on its goal of offering accessible and high-quality therapeutic solutions in regulated markets. The addition of sodium bicarbonate injection further strengthens its injectable portfolio and reflects a continued effort to diversify across product categories within the US pharmaceutical space. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.